Future Diagnostics - Day 2



Chairperson’s Remarks

8:30 Featured Presentation
Grand Challenge in Low Cost and Point-of-Care Diagnostics

John Carrano,Ph.D., President and Founder, Carrano Consulting, LLC

Lack of convenient, accurate, point of care assessment tools in the developing world means that critical health decisions are frequently made without adequate information to ensure that the right decisions are made on heath interventions. New platforms for diagnostics that can be available, affordable, and effective at the point of decision, whether in urban laboratories or the most under resourced and remote villages, are needed. Factors affecting the applicability of diagnostics in these settings in the developing world and examples of opportunities will be discussed.

9:15 Microfluidic Acoustic Cavity Transducers for Future Diagnostics Applications - the Lab-on-Chip Integration of Diagnosis and Treatment

Abraham Lee, Ph.D., Professor, Departments of Biomedical Engineering, Mechanical & Aerospace Engineering; Director, Micro/Nano Fluidics Fundamentals Focus (MF3) Center, University of California, Irvine

Two microfluidic platforms that are based on acoustically active air cavities will be presented. One platform provides rapid and specific diagnostics of infectious diseases based on the immune response detected in a drop of blood. The second platform provides circulating hybrid particles that can both assist in both the diagnostics and treatment of chronic diseases. 

9:45 Functional Porous Silicon Nanostructures for in Vitro and in Vivo Diagnostics

Michael J. Sailor, Ph.D., Professor, Chemistry & Biochemistry, University of California, San Diego

Porous Si possesses several properties that make it advantageous for medical diagnostic applications, including low toxicity, a high surface area, tunable pore sizes and volumes, and flexible surface chemistry. In this talk, the electrochemical synthesis and use of nanostructured porous silicon films, microparticles, and nanoparticles will be described. The use of the photoluminescence and reflective optical response of these materials for in vitro and in vivo sensing and drug delivery applications will be presented.

DiagnosticsForAll 10:15 Patterned-Paper Microfluidics as a Low-Cost Platform for Advanced Point-of-Care Diagnostics in Low-Resource Settings
Una S. Ryan, Ph.D., CEO, Diagnostics For All
New point-of-care diagnostics with increased capabilities that are still easy to use and inexpensive could save millions of lives in developing countries.  Diagnostics For All is creating new low-cost point-of-care diagnostics designed specifically for the developing world.  Our technology enables us to pattern microfluidic channels and detection zones into paper using commercially-available printers.  These devices combine the capabilities of microfluidics with the simplicity of lateral-flow and dipstick tests and can be patterned for a fraction of a cent.  Patterned-paper devices have the potential to give each community health worker the power of a lab in postage stamp-sized pieces of paper.

10:35 Coffee Break with Poster & Exhibit Viewing

11:05 Low Cost Diagnostic Applications for Vaccine Development

Speaker to be Announced

11:35 Universal Platform for Rapid Clinical Diagnostics on Unprocessed Samples

Lori Neely, Ph.D., Director of Molecular Diagnostics, T2 Biosystems

T2 Biosystems is commercializing a universal platform for running molecular, immuno, and cell-based diagnostics. Unprocessed samples ranging from whole blood and urine to needle biopsies can be run on this platform for the diagnosis of a variety of clinical indications including infection, therapeutic monitoring, and cancer. The unique characteristics of the T2 detection technology allow for the consolidation of clinical tests traditionally run in different laboratories, such as molecular assays and immunoassays, onto a single test cartridge and instrument.

Axxin logo12:05 An Advanced Lateral Flow Test Instrument for Rapid Diagnostic at the Point of Care
Paul Lambotte, Ph.D., CSO, Axxin Pty Ltd
The Lateral Flow Test platform is well-established, offering rapid diagnostic at low cost in many medical settings. For several years the CDC, the FDA and many users have cautioned against the limitations of the platform, including its lack of sensitivity and errors linked to subjective visual interpretation and manual reporting of the results. Axxin has developed a reader that intends to respond to such limitations of the lateral flow test platform by allowing higher sensitivity, quantitative results, CLIA compliance (QA, user ID, patient ID, etc.) and full connectivity with LIS, Bluetooth and WiFi systems in a small, affordable package.

12:20 pm Luncheon Presentation or Lunch on Your Own (Sponsorship Opportunity Available, please contact Arnie Wolfson, awolfson@healthtech.com)

1:15 Break


2:00 Chairperson’s Remarks

2:05 Medical Imaging in Thick Tissues Using Spatially and Temporally Modulated Light

Bruce Tromberg, Ph.D., Laser Microbeam and Medical Program, Beckman Laser Institute and Medical Clinic, University of California, Irvine

Medical diagnostic techniques based on near infrared (NIR) transillumination were first introduced more than 70 years ago to detect breast cancer. Although NIR light penetrates tissue to depths of several centimeters, early methods were not successful due to the fact that these approaches were qualitative and did not account for distortions from multiple light scattering. Advances in temporal- and spatial- frequency-domain “photon migration” methods now make it possible to separate light absorption from scattering in thick tissues. Temporal frequency-domain methods measure the phase shift and amplitude of MHz - GHz intensity-modulated waves, while spatial frequency-domain techniques utilize structured light patterns to form wide-field images of tissue optical properties. Both approaches are based on comparing measured data with computational models to form images and acquire spectra. This lecture reviews principles of “diffuse optical spectroscopic imaging (DOSI)” for non-invasively characterizing cellular metabolism, extracellular matrix composition, and vascular dynamics in thick tissues. Measurements of broadband NIR absorption and scattering spectra are used to form images of tissue structure and biochemical composition. Clinical and pre-clinical study results will be shown highlighting DOSI sensitivity to breast tumor metabolism with sufficient sensitivity for cancer detection and therapeutic drug monitoring. These findings will be placed in the context of conventional imaging methods, such as MRI, in order to assess the current and future role of diffuse optics in medical imaging.

2:35 Digital Pathology: Why the Acceleration of Clinical Adoption?

Dirk Soenksen, M.S., M.B.A., Founder & CEO, Aperio Technologies

3:05 Guided by the Light: Examining Tumor Progression with Bioluminescent Probes

Jennifer Prescher, Ph.D., Postdoctoral Fellow, SMIS Program, Stanford University School of Medicine

Human tumors comprise a mixture of cell types with distinct molecular features and behaviors.  How these cellular subsets contribute to cancer progression and metastasis, in many cases, remains poorly understood. Elucidating the functional roles of discrete tumor cell populations—and how they are modulated by interactions with the surrounding microenvironment—requires methods to examine cells in living tissues.  We are using one approach, bioluminescence imaging with light-emitting enzymes (luciferases), to analyze the tumorigenicity and metastatic potential of various human breast cancer cells in mouse models.  We are also developing novel luciferase-based tools to image the interactions between cancer cells and neighboring tissues in vivo.  Collectively, these efforts are clarifying the roles of discrete cell populations in malignancy and shedding light on mechanisms of tumor progression.

3:35 Refreshment Break with Poster & Exhibit Viewing

SET Sensor Electronic Technology4:05 Deep UV LEDs for Future Diagnostics Systems
Remis Gaska, Ph.D., President & CEO, Sensor Electronic Technology

4:20 Sponsored Presentation (Opportunity Available, please contact Arnie Wolfson, awolfson@healthtech.com)

4:35 How Far Away are Validated Surrogate Endpoint Biomarkers for Early Detection of Cancer?

Moderator: Frank L. Meyskens, Jr., M.D., Director, Chao Family Cancer Center; Associate Vice Chancellor, College of Health Sciences, University of California, Irvine


Daniel F. Hayes, M.D., Clinical Director, Breast Oncology Program Stuart B. Padnos Professor in Breast Cancer Research, University of Michigan Comprehensive Cancer Center

Brandon Higgs, Ph.D., Scientist, Translational Sciences, MedImmune

Emanuel F. Petricoin, III, Ph.D.

  • Is a better understanding of specific carcinogenic events likely to improve our track-record in developing useful biomarkers?
  • What is the definition of a validated surrogate endpoint biomarker and would we know when we have achieved this lofty goal?
  • Are randomized clinical trials with correlative biomarkers the only way to develop SEBMs?
  • Is a pre-cancer an acceptable SEBM --in and of itself and/or can it serve as the “cancer endpoint”? If so, when?

5:15 Conference Chairperson’s Closing Remarks

Gregory A. Weiss, Ph.D., Professor, Departments of Chemistry, Molecular Biology & Biochemistry, University of California, Irvine

5:30 End of conference

By Series:
By Region: